199 related articles for article (PubMed ID: 20952418)
1. Tribal ethnicity and CYP2B6 genetics in Ugandan and Zimbabwean populations in the UK: implications for efavirenz dosing in HIV infection.
Jamshidi Y; Moreton M; McKeown DA; Andrews S; Nithiyananthan T; Tinworth L; Holt DW; Sadiq ST
J Antimicrob Chemother; 2010 Dec; 65(12):2614-9. PubMed ID: 20952418
[TBL] [Abstract][Full Text] [Related]
2. CYP2B6 genotype is a strong predictor of systemic exposure to efavirenz in HIV-infected Zimbabweans.
Maimbo M; Kiyotani K; Mushiroda T; Masimirembwa C; Nakamura Y
Eur J Clin Pharmacol; 2012 Mar; 68(3):267-71. PubMed ID: 21901344
[TBL] [Abstract][Full Text] [Related]
3. CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients.
Kwara A; Lartey M; Sagoe KW; Kenu E; Court MH
AIDS; 2009 Oct; 23(16):2101-6. PubMed ID: 19779319
[TBL] [Abstract][Full Text] [Related]
4. High predictive value of CYP2B6 SNPs for steady-state plasma efavirenz levels in South African HIV/AIDS patients.
Swart M; Skelton M; Ren Y; Smith P; Takuva S; Dandara C
Pharmacogenet Genomics; 2013 Aug; 23(8):415-27. PubMed ID: 23778320
[TBL] [Abstract][Full Text] [Related]
5. CYP2B6 G516T genotyping in a UK cohort of HIV-positive patients: polymorphism frequency and influence on efavirenz discontinuation.
Powers V; Ward J; Gompels M
HIV Med; 2009 Sep; 10(8):520-3. PubMed ID: 19486190
[TBL] [Abstract][Full Text] [Related]
6. CYP2B6 (c.516G-->T) and CYP2A6 (*9B and/or *17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients.
Kwara A; Lartey M; Sagoe KW; Rzek NL; Court MH
Br J Clin Pharmacol; 2009 Apr; 67(4):427-36. PubMed ID: 19371316
[TBL] [Abstract][Full Text] [Related]
7. High prevalence of the CYP2B6 516G-->T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe.
Nyakutira C; Röshammar D; Chigutsa E; Chonzi P; Ashton M; Nhachi C; Masimirembwa C
Eur J Clin Pharmacol; 2008 Apr; 64(4):357-65. PubMed ID: 18057928
[TBL] [Abstract][Full Text] [Related]
8. CYP2B6 18492T->C polymorphism compromises efavirenz concentration in coinfected HIV and tuberculosis patients carrying CYP2B6 haplotype *1/*1.
Manosuthi W; Sukasem C; Thongyen S; Nilkamhang S; Manosuthi S; Sungkanuparph S
Antimicrob Agents Chemother; 2014; 58(4):2268-73. PubMed ID: 24492364
[TBL] [Abstract][Full Text] [Related]
9. Haplotype structure of CYP2B6 and association with plasma efavirenz concentrations in a Chilean HIV cohort.
Carr DF; la Porte CJ; Pirmohamed M; Owen A; Cortes CP
J Antimicrob Chemother; 2010 Sep; 65(9):1889-93. PubMed ID: 20639527
[TBL] [Abstract][Full Text] [Related]
10. CYP2B6 Haplotype Predicts Efavirenz Plasma Concentration in Black South African HIV-1-Infected Children: A Longitudinal Pediatric Pharmacogenomic Study.
Reay R; Dandara C; Viljoen M; Rheeders M
OMICS; 2017 Aug; 21(8):465-473. PubMed ID: 28816644
[TBL] [Abstract][Full Text] [Related]
11. Pharmacogenetic markers of CYP2B6 associated with efavirenz plasma concentrations in HIV-1 infected Thai adults.
Sukasem C; Cressey TR; Prapaithong P; Tawon Y; Pasomsub E; Srichunrusami C; Jantararoungtong T; Lallement M; Chantratita W
Br J Clin Pharmacol; 2012 Dec; 74(6):1005-12. PubMed ID: 22471906
[TBL] [Abstract][Full Text] [Related]
12. CYP2B6 variants and plasma efavirenz concentrations during antiretroviral therapy in Port-au-Prince, Haiti.
Leger P; Dillingham R; Beauharnais CA; Kashuba AD; Rezk NL; Fitzgerald DW; Pape JW; Haas DW
J Infect Dis; 2009 Sep; 200(6):955-64. PubMed ID: 19659438
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of efavirenz when co-administered with rifampin in TB/HIV co-infected patients: pharmacogenetic effect of CYP2B6 variation.
Kwara A; Lartey M; Sagoe KW; Xexemeku F; Kenu E; Oliver-Commey J; Boima V; Sagoe A; Boamah I; Greenblatt DJ; Court MH
J Clin Pharmacol; 2008 Sep; 48(9):1032-40. PubMed ID: 18728241
[TBL] [Abstract][Full Text] [Related]
14. A single-nucleotide polymorphism in CYP2B6 leads to >3-fold increases in efavirenz concentrations in plasma and hair among HIV-infected women.
Gandhi M; Greenblatt RM; Bacchetti P; Jin C; Huang Y; Anastos K; Cohen M; Dehovitz JA; Sharp GB; Gange SJ; Liu C; Hanson SC; Aouizerat B;
J Infect Dis; 2012 Nov; 206(9):1453-61. PubMed ID: 22927450
[TBL] [Abstract][Full Text] [Related]
15. Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients.
Wyen C; Hendra H; Vogel M; Hoffmann C; Knechten H; Brockmeyer NH; Bogner JR; Rockstroh J; Esser S; Jaeger H; Harrer T; Mauss S; van Lunzen J; Skoetz N; Jetter A; Groneuer C; Fätkenheuer G; Khoo SH; Egan D; Back DJ; Owen A;
J Antimicrob Chemother; 2008 Apr; 61(4):914-8. PubMed ID: 18281305
[TBL] [Abstract][Full Text] [Related]
16. Impact of pharmacogenetic markers of CYP2B6, clinical factors, and drug-drug interaction on efavirenz concentrations in HIV/tuberculosis-coinfected patients.
Manosuthi W; Sukasem C; Lueangniyomkul A; Mankatitham W; Thongyen S; Nilkamhang S; Manosuthi S; Sungkanuparph S
Antimicrob Agents Chemother; 2013 Feb; 57(2):1019-24. PubMed ID: 23254426
[TBL] [Abstract][Full Text] [Related]
17. Associations between CYP2B6 polymorphisms and pharmacokinetics after a single dose of nevirapine or efavirenz in African americans.
Haas DW; Gebretsadik T; Mayo G; Menon UN; Acosta EP; Shintani A; Floyd M; Stein CM; Wilkinson GR
J Infect Dis; 2009 Mar; 199(6):872-80. PubMed ID: 19239339
[TBL] [Abstract][Full Text] [Related]
18. Influence of CYP2B6 516G>T polymorphism and interoccasion variability (IOV) on the population pharmacokinetics of efavirenz in HIV-infected South African children.
Viljoen M; Karlsson MO; Meyers TM; Gous H; Dandara C; Rheeders M
Eur J Clin Pharmacol; 2012 Apr; 68(4):339-47. PubMed ID: 22057858
[TBL] [Abstract][Full Text] [Related]
19. Efavirenz plasma concentrations and cytochrome 2B6 polymorphisms.
Lindfelt T; O'Brien J; Song JC; Patel R; Winslow DL
Ann Pharmacother; 2010 Oct; 44(10):1572-8. PubMed ID: 20841522
[TBL] [Abstract][Full Text] [Related]
20. Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study.
Ribaudo HJ; Liu H; Schwab M; Schaeffeler E; Eichelbaum M; Motsinger-Reif AA; Ritchie MD; Zanger UM; Acosta EP; Morse GD; Gulick RM; Robbins GK; Clifford D; Haas DW
J Infect Dis; 2010 Sep; 202(5):717-22. PubMed ID: 20662624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]